0.00

100.00% -6.365

Cyclacel Pharmaceuticals Inc (CYCC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cyclacel Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Previous Close:

$6.365

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$15.16M

Revenue:

$74,000

Net Income/Loss:

$-13.43M

P/E Ratio:

0.00

EPS:

-9.4

Net Cash Flow:

$-10.54M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

52-Week Range:

$0.00

$19.87

Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile

Name

Cyclacel Pharmaceuticals Inc

Sector

Healthcare (1120)

Industry

Biotechnology (621)

Phone

908-517-7330

Address

200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CYCC's Discussions on Twitter

Compare CYCC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CYCC Cyclacel Pharmaceuticals Inc	0.00	15.16M	74,000	-13.43M	-10.54M	-9.40
VRTX Vertex Pharmaceuticals Inc	458.85	117.69B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	780.78	83.72B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	783.72	48.79B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	359.12	52.62B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	333.15	37.39B	4.98B	69.59M	525.67M	0.5197

Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-22	Resumed	Oppenheimer	Outperform
Apr-27-20	Resumed	ROTH Capital	Buy
Sep-07-18	Initiated	Ladenburg Thalmann	Buy
Oct-16-15	Initiated	H.C. Wainwright	Buy
Feb-04-10	Initiated	Roth Capital	Buy
Oct-28-09	Initiated	Merriman	Buy
Aug-12-08	Initiated	Piper Jaffray	Buy
Mar-12-08	Reiterated	Cantor Fitzgerald	Buy
Mar-12-08	Reiterated	Collins Stewart	Buy
Mar-12-08	Reiterated	Needham & Co	Buy
Nov-27-07	Reiterated	Cantor Fitzgerald	Buy
Aug-10-07	Reiterated	Cantor Fitzgerald	Buy
Jun-04-07	Reiterated	Needham & Co	Buy
Apr-23-07	Initiated	Lazard Capital	Buy
Apr-10-07	Initiated	Cantor Fitzgerald	Buy

View All

Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News

Jan 11, 2026

CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com

Jan 11, 2026

Jan 08, 2026

Is Cyclacel Pharmaceuticals Inc. stock a bargain at current levels2025 Earnings Impact & Daily Profit Focused Stock Screening - ulpravda.ru

Jan 08, 2026

Jan 06, 2026

Cyclacel stock dips after trimming 270% surge amid volatility concerns - MSN

Jan 06, 2026

Why Cyclacel Pharmaceuticals Inc. stock remains on buy lists2026 world cup usa national team semifinals young talents high defensive line match prediction preview - ulpravda.ru

Jan 06, 2026

Dec 30, 2025

PPL Corporation PP9 Stock Analysis and ForecastVolatility Index Analysis & Your Free Entry to Smart Investing Starts Here - earlytimes.in

Dec 30, 2025

Dec 27, 2025